ATE237338T1 - Allogene parakrine cytokine tumor impfstoffe - Google Patents

Allogene parakrine cytokine tumor impfstoffe

Info

Publication number
ATE237338T1
ATE237338T1 AT96945109T AT96945109T ATE237338T1 AT E237338 T1 ATE237338 T1 AT E237338T1 AT 96945109 T AT96945109 T AT 96945109T AT 96945109 T AT96945109 T AT 96945109T AT E237338 T1 ATE237338 T1 AT E237338T1
Authority
AT
Austria
Prior art keywords
cell line
tumor cell
allogene
tumor
tumor vaccines
Prior art date
Application number
AT96945109T
Other languages
English (en)
Inventor
Elizabeth M Jaffee
Drew M Pardoll
Hyam I Levitsky
Original Assignee
Univ Johns Hopkins Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24318022&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE237338(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Johns Hopkins Med filed Critical Univ Johns Hopkins Med
Application granted granted Critical
Publication of ATE237338T1 publication Critical patent/ATE237338T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001139—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT96945109T 1995-12-28 1996-12-26 Allogene parakrine cytokine tumor impfstoffe ATE237338T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57970895A 1995-12-28 1995-12-28
PCT/US1996/020802 WO1997024132A1 (en) 1995-12-28 1996-12-26 Allogeneic paracrine cytokine tumor vaccines

Publications (1)

Publication Number Publication Date
ATE237338T1 true ATE237338T1 (de) 2003-05-15

Family

ID=24318022

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96945109T ATE237338T1 (de) 1995-12-28 1996-12-26 Allogene parakrine cytokine tumor impfstoffe

Country Status (7)

Country Link
EP (1) EP0869803B1 (de)
JP (1) JP2000502711A (de)
AT (1) ATE237338T1 (de)
AU (1) AU1355697A (de)
DE (1) DE69627527T2 (de)
ES (1) ES2191784T3 (de)
WO (1) WO1997024132A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9620350D0 (en) 1996-09-30 1996-11-13 Maudsley David J Cancer vaccine
EP0893507A1 (de) * 1997-07-25 1999-01-27 Institut Gustave Roussy Verwendung von MHC Klass II Liganden (CD4 und LAG-3) als Adjuvanz für Impfungen und von LAG-3 in der Behandlung von Krebs
DE19832840C1 (de) * 1998-07-21 2000-06-08 Kerkmann Tucek Aida Mittel zur Immuntherapie von Tumorerkrankungen
GB9827103D0 (en) 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
GB9827104D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
CA2374294A1 (en) * 1999-05-21 2000-11-30 Onyvax Limited New vaccine formulations - 2
WO2000071156A2 (en) * 1999-05-21 2000-11-30 Onyvax Limited New vaccine formulations-3
GB9911823D0 (en) * 1999-05-21 1999-07-21 Onyvax Ltd New vaccine formulations
CA2404388C (en) 2000-04-01 2010-06-15 Onyvax Limited New prostate cell lines
WO2003039592A2 (de) * 2001-11-09 2003-05-15 Medigene Aktiengesellschaft Zelluläre impfstoffe mit adjuvanzien
US20090110702A1 (en) 2002-07-12 2009-04-30 The Johns Hopkins University Mesothelin Vaccines and Model Systems and Control of Tumors
US9200036B2 (en) 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
EP1575500A4 (de) 2002-07-12 2007-01-03 Univ Johns Hopkins Mesothelin-vakzine und model systems
US7176022B2 (en) 2002-12-20 2007-02-13 Cell Genesys, Inc. Directly injectable formulations which provide enhanced cryoprotection of cell products
US20050019336A1 (en) 2003-07-23 2005-01-27 Dalgleish Angus George Human prostate cell lines in cancer treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2002025A1 (en) * 1988-11-02 1990-05-02 Geary W. Collins Continuous mammalian cell lines having monocyte-macrophage characteristics and their establishment in vitro
WO1992005262A1 (en) * 1990-09-14 1992-04-02 The John Hopkins University Methods and compositions for genetic therapy and potentiation of anti-tumor immunity
WO1994004196A1 (en) * 1992-08-14 1994-03-03 Imperial Cancer Research Technology Limited Tumour therapy

Also Published As

Publication number Publication date
EP0869803B1 (de) 2003-04-16
AU1355697A (en) 1997-07-28
ES2191784T3 (es) 2003-09-16
JP2000502711A (ja) 2000-03-07
EP0869803A1 (de) 1998-10-14
DE69627527D1 (en) 2003-05-22
DE69627527T2 (de) 2004-03-04
WO1997024132A1 (en) 1997-07-10

Similar Documents

Publication Publication Date Title
ATE237338T1 (de) Allogene parakrine cytokine tumor impfstoffe
ATE505206T1 (de) Verwendung des melanomdifferenzierungs assoziierten gens (mda-7) zur umwandlung eines krebsphänotyps
FI935174A0 (fi) Tumoeravstoetande antigenprekursorer, tumoeravstoetande antigener och anvaendning av dem
DE3885317D1 (de) Makromolekulare Platin-Antitumorverbindungen.
ATE420192T1 (de) Verfahren zur verringerung der antigenität des adeno-assoziierten virus strukturproteins
DK0873332T3 (da) Discodermolidforbindelser samt farmaceutiske sammensætninger indeholdende dem til cancerterapi
BR8301918A (pt) Proteina,sequencia de dna,veiculo de expressao replicavel,microorganismo ou cultura celular,plasmideo,composicao,cultura de celulas,utilizacao de tal proteina,processo de expressao,processo para producao de um veiculo de expressao e processo para preparacao de uma proteina uroquinase
ES8307263A1 (es) Un procedimiento para la preparacion de fosfonamidas sustituidas.
EE9900481A (et) Väikesed molekulid, mida kasutatakse põletikuliste haiguste raviks
FI943750A0 (fi) Menetelmä nekroositekijän valmistamiseksi
EA199801031A1 (ru) Ингибиторы протеинфарнезилтрансферазы
AU7411794A (en) Method of tumor treatment
RU94042393A (ru) Галихондрины, родственные соединения и способ лечения опухоли у млекопитающих
HU9501288D0 (en) Recombinant method and host for manufacture of xylitol
DE3477791D1 (en) Nucleoside process
HUT61202A (en) Process for producing pharmaceutical compositions neutralizing procoagulant activity caused by tumour cells
DE69332688D1 (de) Verwendung von modifiziertem c-reaktiven protein zur herstellung eines medikaments zur behandlung von krebs
ZA89447B (en) Composition and method for protecting against diseases caused by microorganisms
DE69739658D1 (de) Säugetiergene, die an der viralen infektion beteiligt sind
ATE248914T1 (de) Allogenes vakzin und synthesemethode für selbiges
EA200000522A1 (ru) 5-htагонисты
EP0255717A3 (de) Gangliosid-Derivate und Verfahren zur Herstellung davon
DE69724472D1 (de) Selenophen-antitumormittel
BG35749A3 (en) Method for preparing 20- dihydro- 20, 23- dideoxytilonolide
EP0925064A4 (de) 5-ANDROSTEN 3-beta, 17-alpha DIOL ALS TUMORWACHSTUMSHEMMER

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties